Application progress of high-throughput sequencing in antiphospholipid syndrome.
10.3760/cma.j.cn112150-20220609-00594
- VernacularTitle:高通量测序在抗磷脂综合征中应用的新进展
- Author:
Qi LIU
1
;
Shuo YANG
2
;
Li Yan CUI
2
Author Information
1. Institute of Medical Technology, Peking University Health Science Center, Beijing 100191, China.
2. Department of Clinical Laboratory, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Female;
Pregnancy;
Humans;
Antiphospholipid Syndrome/diagnosis*;
Thrombosis/complications*;
Antibodies, Antiphospholipid;
Biomarkers;
High-Throughput Nucleotide Sequencing
- From:
Chinese Journal of Preventive Medicine
2023;57(5):766-770
- CountryChina
- Language:Chinese
-
Abstract:
Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and(or) morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of patients, the problem of APS diagnosis, prognosis judgment and risk assessment may not be solved only from antibody level. It is necessary to use new technologies and multiple dimensions to explore novel APS biomarkers. The application of next generation sequencing (NGS) technology in diseases with high incidence of somatic mutations, such as genetic diseases and tumors, has been very mature. Thus, gradually understanding the research and application progress of APS by NGS technology from genome, transcriptome, epigenome and other aspects is meaningful. This article reviews the related research of NGS technology in APS, and provide more reference for the deep understanding of the APS-related screening markers and disease pathogenesis.
